|
As
of September 30, 2021, there were the following potentially dilutive
securities that were excluded from diluted net loss per share because their effect would be anti-dilutive:
SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE
| Shares from the conversion of Series B Preferred Stock not inclusive of dividends |
|
|
9,431,250 |
|
| Shares from the conversion of Series E-1 Preferred Stock (subject to vesting in 2021 through 2023 and potential forfeiture) |
|
|
8,500,000 |
|
| Shares from common stock options |
|
|
1,112,619 |
|
| Shares from common stock warrants |
|
|
7,559,289 |
|
| Shares from the conversion of debentures |
|
|
218,750 |
|
| Shares from the conversion of redeemable convertible preferred stock (based upon an assumed conversion price at September 30, 2021 of $0.16 per share; inclusive of cumulative dividends which may be converted to shares of common stock under certain conditions) |
|
|
4,286,875 |
|
As
of September 30, 2020, there were the following potentially dilutive
securities that were excluded from diluted net loss per share because their effect would be anti-dilutive:
| Shares from common stock options |
|
|
468,619 |
|
| Shares from common stock warrants |
|
|
46,154 |
|
| Shares from the conversion of debentures |
|
|
66,000 |
|
| Shares that may be converted from Bridge Notes (based upon an assumed conversion price at September 30, 2020 of $1.98 per share) |
|
|
8,079,617 |
|
| Shares from the conversion of redeemable convertible preferred stock (inclusive of cumulative dividends which may be converted to shares of common stock under certain conditions). |
|
|
3,522,591 |
|
|